In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma

[1]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[2]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[3]  John Lamb,et al.  Guide Swap enables genome-scale pooled CRISPR–Cas9 screening in human primary cells , 2018, Nature Methods.

[4]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[5]  A. Ashworth,et al.  Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function , 2018, Cell.

[6]  K. Ligon,et al.  Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 , 2018, Neuro-oncology.

[7]  F. DiMeco,et al.  Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy , 2018, Science Translational Medicine.

[8]  R. Vijay,et al.  Interleukin‐10 Directly Inhibits CD8+ T Cell Function by Enhancing N‐Glycan Branching to Decrease Antigen Sensitivity , 2018, Immunity.

[9]  Christopher W Mount,et al.  Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas , 2018, Nature Medicine.

[10]  Randall J. Platt,et al.  Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR–mediated direct in vivo screening , 2018, Science Advances.

[11]  G. Ronzitti,et al.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy , 2017, Molecular therapy. Methods & clinical development.

[12]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[13]  A. Yoshimura,et al.  Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. , 2017, Cell reports.

[14]  Randall J. Platt,et al.  AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma , 2017, Nature Neuroscience.

[15]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[16]  A. Brandes,et al.  OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .

[17]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[18]  Christopher M. Jackson,et al.  Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.

[19]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[20]  Christopher M. Jackson,et al.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas , 2016, Clinical Cancer Research.

[21]  Lior Pachter,et al.  Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.

[22]  V. Kuchroo,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[23]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[24]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[25]  D. Lodygin,et al.  Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid , 2016, Nature.

[26]  W. Han,et al.  Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy , 2016, Journal of the National Cancer Institute.

[27]  D. Hafler,et al.  Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.

[28]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[29]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[30]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[31]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[32]  Meagan E. Sullender,et al.  Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.

[33]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[34]  Bjoern Peters,et al.  In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation. , 2014, Immunity.

[35]  R. Bernards.  Finding effective cancer therapies through loss of function genetic screens. , 2014, Current opinion in genetics & development.

[36]  J. C. Love,et al.  In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.

[37]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[38]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[39]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[40]  W. Curry,et al.  Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors , 2012, Journal of immunotherapy.

[41]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[42]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[43]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[44]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[45]  Boris Jerchow,et al.  Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates , 2009, Nature Genetics.

[46]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[47]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[48]  J. Dennis,et al.  N-Acetylglucosaminyltransferase V (Mgat5)-Mediated N-Glycosylation Negatively Regulates Th1 Cytokine Production by T Cells1 , 2004, The Journal of Immunology.

[49]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[50]  In-Jeong Kim,et al.  Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1 , 2004, The Journal of Immunology.

[51]  D. Vignali,et al.  Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31 , 2002, The Journal of Immunology.

[52]  J. Dennis,et al.  Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation , 2001, Nature.

[53]  J. Dennis,et al.  Suppression of tumor growth and metastasis in Mgat5-deficient mice , 2000, Nature Medicine.

[54]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[55]  K. Sugiura,et al.  Studies in a tumor spectrum. II. The growth of a variety of mouse and rat tumors , 1952 .

[56]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[57]  S. Sugano,et al.  Alteration of immune responses by N-acetylglucosaminyltransferase V during allergic airway inflammation. , 2011, Allergology international : official journal of the Japanese Society of Allergology.

[58]  Jos Jonkers,et al.  A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites , 2009, Nature Protocols.

[59]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[60]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .

[61]  C. Stock,et al.  Studies in a tumor spectrum. II. The effect of 2,4,6-triethylenimino-s-triazine on the growth of a variety of mouse and rat tumors. , 1952, Cancer.